Market Place
Sourcing Support
Arcturus Therapeutics To Attend Upcoming Investor Conference
05 Mar 2026 //
PHARMIWEB
Arcturus Therapeutics Unveils 2025 Financials & Pipeline Progress
03 Mar 2026 //
BUSINESSWIRE
Arcturus Therapeutics To Release Q4 2025 Financials Result
17 Feb 2026 //
BUSINESSWIRE
Arcturus Therapeutics at 44th JPM Healthcare Conference
08 Jan 2026 //
BUSINESSWIRE
Arcturus Therapeutics To Attend Upcoming Investor Conference
24 Nov 2025 //
BUSINESSWIRE
Arcturus Therapeutics Unveils Q3 2025 Financial Update
10 Nov 2025 //
BUSINESS WIRE
Arcturus Therapeutics To Release Q3 Financials And Corporate
28 Oct 2025 //
BUSINESSWIRE
Arcturus Plunges On Mixed Cystic Fibrosis Inhaled mRNA Drug Data
23 Oct 2025 //
BIOSPACE
Arcturus’ Stock Halves on Cystic Fibrosis Readout
22 Oct 2025 //
BUSINESSWIRE
Innovative Therapeutics Pipeline Boosts Industry Market Growth
15 Sep 2025 //
PR NEWSWIRE
Arcturus Therapeutics to Attend Upcoming Investor Conferences
26 Aug 2025 //
BUSINESSWIRE
Arcturus Therapeutics to Report Second Quarter Financial Results
24 Jul 2025 //
BUSINESSWIRE
Arcturus Therapeutics to Attend Upcoming Investor Conferences
29 May 2025 //
BUSINESSWIRE
Arcturus doubles down on mRNA, axes several early-stage assets
13 May 2025 //
FIERCE BIOTECH
Arcturus Therapeutics Q1 2025 Financial Update & Pipeline Progress
12 May 2025 //
BUSINESSWIRE
Arcturus Therapeutics gets FDA Fast Track for ARCT-2304 Vaccine
10 Apr 2025 //
BUSINESSWIRE
Arcturus Therapeutics Announces Q4 and FY 2024 Update
06 Mar 2025 //
BUSINESSWIRE
Europe Approves CSL and Arcturus Therapeutics’ Kostaive
14 Feb 2025 //
BUSINESSWIRE
Arcturus Announces Appointment of Moncef as Chair Designate
04 Feb 2025 //
BUSINESSWIRE
Arcturus Therapeutics to Present at Guggenheim Biotech Conference
30 Jan 2025 //
BUSINESSWIRE
Arcturus Starts Phase 2 Dosing For CF And OTC Deficiency
06 Jan 2025 //
BUSINESSWIRE
Arcturus Therapeutics to Present at J.P. Morgan Healthcare Conf.
16 Dec 2024 //
BUSINESSWIRE
Arcturus Therapeutics to Attend Upcoming Investor Conferences
26 Nov 2024 //
BUSINESSWIRE
Arcturus Receives FDA Clearance for H5N1 Flu Vaccine Trial
11 Nov 2024 //
BUSINESSWIRE
Arcturus Therapeutics Q3 2024 Results & Pipeline Progress Update
07 Nov 2024 //
BUSINESSWIRE
Arcturus Therapeutics to Report Q3 Results on Nov 7, 2024
31 Oct 2024 //
BUSINESSWIRE
Japan Approves CSL And Arcturus` Updated COVID-19 Vaccine For JN.1 Strain
13 Sep 2024 //
BUSINESSWIRE
Arcturus Therapeutics Gets FDA Clearance for ARCT-032 for Cystic Fibrosis
03 Sep 2024 //
BUSINESSWIRE
Arcturus To Present At Canaccord Genuity Growth Conference
01 Aug 2024 //
BUSINESSWIRE
Arcturus teases data from small trial of inhalable cystic fibrosis mRNA therapy
29 May 2024 //
ENDPTS
Nature Comms: CSL, Arcturus COVID-19 Vaccine Efficacy, Tolerability
20 May 2024 //
PR NEWSWIRE
Meiji Seika to supply Japan with self-amplifying mRNA Covid-19 vaccine
22 Mar 2024 //
ENDPTS
PassPort Technologies Commences Collaborative Research with Arcturus
05 Jan 2024 //
PR NEWSWIRE
CSL and Arcturus Therapeutics’ ARCT-154 Approved for COVID in Adults
28 Nov 2023 //
BUSINESSWIRE
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS
04 Oct 2023 //
BUSINESSWIRE
Arcturus sa-mRNA COVID boosters induce immune response in ph. 2
19 Sep 2023 //
FIERCE BIOTECH
Study Shows sa-mRNA Vaccines Offer Robust Protection Against COVID-19 Variants
19 Sep 2023 //
BUSINESSWIRE
Arcturus and CSL Announce EMA Validates MAA for ARCT-154
05 Sep 2023 //
BUSINESSWIRE
Arcturus, ARCALIS Awarded $115M in Grants from the Japanese Government
23 Aug 2023 //
CONTRACT PHARMA
Japan awarded $115M to Arcturus JV to boost mRNA manufacturing
15 Aug 2023 //
FIERCE PHARMA
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810
01 Jun 2023 //
BUSINESSWIRE
Arcturus to Report First Quarter Financial Results and Provide Corporate
26 Apr 2023 //
BUSINESSWIRE
Arcturus Announces Clinical Trial Application for ARCT-032 Received Approval
31 Jan 2023 //
BUSINESSWIRE
